Golubovskaya Vita
Promab Biotechnologies, Richmond, CA 94806, USA.
Front Biosci (Landmark Ed). 2022 Apr 2;27(4):121. doi: 10.31083/j.fbl2704121.
CAR (Chimeric antigen receptor)-T cell therapy has become a very promising type of immunotherapy against hematological cancers. This report is focused on CAR-T cells targeting immune checkpoint proteins expressed on tumor cells. The CD70, CD47, CD80, CD86, B7H3, B7H4, PDL-1, TIGIT CAR-T cells and other CAR-T cells are discussed as an effective approach to deplete tumor cells expressing checkpoint proteins. CAR-T cell therapy targeting checkpoint pathways is a promising therapy to decrease inhibitory signaling pathways. The review highlights future directions and perspectives in CAR-T cells targeting immune checkpoint pathways.
嵌合抗原受体（CAR）-T细胞疗法已成为一种非常有前景的针对血液系统癌症的免疫疗法。本报告聚焦于靶向肿瘤细胞上表达的免疫检查点蛋白的CAR-T细胞。讨论了CD70、CD47、CD80、CD86、B7H3、B7H4、程序性死亡受体1（PDL-1）、T细胞免疫球蛋白和ITIM结构域（TIGIT）CAR-T细胞等作为清除表达检查点蛋白的肿瘤细胞的有效方法。靶向检查点通路的CAR-T细胞疗法是一种有前景的减少抑制性信号通路的疗法。本综述强调了靶向免疫检查点通路的CAR-T细胞的未来方向和前景。
